Moderna, Inc.
MRNANext catalyst
mRNA-3745
Glycogen Storage Disease
Get an email about MRNA's next catalysts
Track Moderna (MRNA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
5 upcoming, 1 past
mRNA-3745 Phase 2 Est. Readout
Primary completion for mRNA-3745 trial (NCT05095727) in Glycogen Storage Disease
SourcemRNA-1018-H5 Phase 3 Est. Readout
Estimated primary completion for mRNA-1018-H5 trial (NCT07496450) in Influenza. Topline data typically follows completion by weeks to months.
SourcemRNA-1403 Phase 3 Est. Readout (Nova 301)
Primary completion for mRNA-1403 trial (NCT06592794) in Acute Gastroenteritis
SourcemRNA-1647 Phase 2 Est. Readout
Primary completion for mRNA-1647 trial (NCT05575492) in Cytomegalovirus
SourcemRNA-3927 Phase 2 Est. Readout
Primary completion for mRNA-3927 trial (NCT04159103) in Propionic Acidemia
SourceHow MRNA's past catalysts played out
Market Overview
Stock performance and key metrics
Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
WebsitemRNA-1273.214
SARS-CoV-2
mRNA-1083
COVID-19
mRNA-1283.815
COVID-19
mRNA-1283.222
COVID-19
mRNA-1345
Respiratory Syncytial Virus
mRNA-4157
Personalized Cancer Vaccine
Melanoma
Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (Comirnaty®)
Immunocompromised Patients
Fluarix Tetra
Seasonal Influenza
Afluria® Quadrivalent
Respiratory Syncytial Virus
mRNA-1403
Acute Gastroenteritis
Pembrolizumab coformulated with berahyaluronidase alfa
Non-small Cell Lung Cancer
mRNA-1273.211
SARS-CoV-2
mRNA-1273.213
SARS-CoV-2
mRNA-1010
Seasonal Influenza
mRNA-1273.529
SARS-CoV-2
mRNA-1273
SARS-CoV-2
mRNA-1273.231
SARS-CoV-2
Fluzone HD
Respiratory Syncytial Virus
Influenza Vaccine
SARS-CoV-2
Fluarix®
Seasonal Influenza
mRNA-1273.617.2
SARS-CoV-2
mRNA-1273.222
COVID-19
mRNA-1273.815
COVID-19
Investigational mRNA-1273.815
SARS-CoV-2
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Seasonal Influenza
mRNA-1018-H5
Influenza
Intismeran autogene
Non-small Cell Lung Cancer
Influsplit® Tetra
Seasonal Influenza
Moderna COVID-19 Vaccine, mRNA-1273
Immunocompromised Patients
mRNA-1283
COVID-19
mRNA-1083 Composition 1 Dose B
Influenza
mRNA-1083.2
SARS-CoV-2
mRNA-1045
Influenza
mRNA-1283.529
SARS-CoV-2
mRNA-1083 Composition 3 Dose B
Influenza
mRNA-1018 for H5 Only
Influenza
mRNA-1083 Composition 1 Dose A Lot B
Influenza
mRNA-1083 Composition 2 Dose A
Influenza
BEXSERO
Genital Herpes
mRNA-1011.2
Seasonal Influenza
mRNA-1018 for H5 Only-CG
Influenza
mRNA-1018 for H7N9
Influenza
mRNA-1083.3
SARS-CoV-2
mRNA-1083 Composition 1 Dose C
Influenza
mRNA-1083 Composition 3 Dose A
Influenza
mRNA-1010.6
Influenza
mRNA-1018 for H7 Only
Influenza
mRNA-1083 Composition 2 Dose B
Influenza
mRNA-1012.1
Seasonal Influenza
mRNA-1020
Seasonal Influenza
mRNA-1647
Cytomegalovirus Infection
mRNA-1030
Seasonal Influenza
mRNA-1769
Smallpox
mRNA-1608
Genital Herpes
mRNA-1018 for H5N8
Influenza
mRNA-3927
Propionic Acidemia
mRNA-1073
SARS-CoV-2
mRNA-1283.211
SARS-CoV-2
mRNA-1468
Herpes Zoster
mRNA-1893
Zika Virus
mRNA-1083 Composition 1 Dose A Lot A
Influenza
mRNA-3705
Methylmalonic Acidemia
mRNA-3745
Glycogen Storage Disease
mRNA-1010.4
Influenza
Egg-based Quadrivalent Influenza Vaccine
Influenza
mRNA-1195
Multiple Sclerosis
mRNA-1011.1
Seasonal Influenza
mRNA-1405
Norovirus Acute Gastroenteritis
mRNA-1189
Epstein-Barr Virus Infection
mRNA-1975
Lyme Disease
Influenza Vaccine 1
SARS-CoV-2
mRNA-2808
Relapsed or Refractory Multiple Myeloma
mRNA-1982
Lyme Disease
mRNA-1273.214 Vaccine
COVID-19 Pandemic
mRNA-1273.351
SARS-CoV-2
mRNA-4359
Advanced Solid Tumors
IVA
Cystic Fibrosis
mRNA-1083.1
SARS-CoV-2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mRNA-1273.214 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1083 | Phase 3 | COVID-19 | - | - |
mRNA-1283.815 | Phase 3 | COVID-19 | - | - |
mRNA-1283.222 | Phase 3 | COVID-19 | - | - |
mRNA-1345 | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-4157 Personalized Cancer Vaccine | Phase 3 | Melanoma | OrphanFast TrackBreakthrough | - |
Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (Comirnaty®) | Phase 3 | Immunocompromised Patients | - | - |
Fluarix Tetra | Phase 3 | Seasonal Influenza | - | - |
Afluria® Quadrivalent | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1403 | Phase 3 | Acute Gastroenteritis | - | - |
Pembrolizumab coformulated with berahyaluronidase alfa | Phase 3 | Non-small Cell Lung Cancer | - | - |
mRNA-1273.211 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.213 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1010 | Phase 3 | Seasonal Influenza | Fast Track | - |
mRNA-1273.529 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.231 | Phase 3 | SARS-CoV-2 | - | - |
Fluzone HD | Phase 3 | Respiratory Syncytial Virus | - | - |
Influenza Vaccine | Phase 3 | SARS-CoV-2 | - | - |
Fluarix® | Phase 3 | Seasonal Influenza | - | - |
mRNA-1273.617.2 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.222 | Phase 3 | COVID-19 | - | - |
mRNA-1273.815 | Phase 3 | COVID-19 | - | - |
Investigational mRNA-1273.815 | Phase 3 | SARS-CoV-2 | - | - |
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza | - | - |
mRNA-1018-H5 | Phase 3 | Influenza | - | - |
Intismeran autogene | Phase 3 | Non-small Cell Lung Cancer | - | - |
Influsplit® Tetra | Phase 3 | Seasonal Influenza | - | - |
Moderna COVID-19 Vaccine, mRNA-1273 | Phase 3 | Immunocompromised Patients | - | - |
mRNA-1283 | Phase 3 | COVID-19 | Fast Track | - |
mRNA-1083 Composition 1 Dose B | Phase 2 | Influenza | - | - |
mRNA-1083.2 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1045 | Phase 2 | Influenza | - | - |
mRNA-1283.529 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1083 Composition 3 Dose B | Phase 2 | Influenza | - | - |
mRNA-1018 for H5 Only | Phase 2 | Influenza | - | - |
mRNA-1083 Composition 1 Dose A Lot B | Phase 2 | Influenza | - | - |
mRNA-1083 Composition 2 Dose A | Phase 2 | Influenza | - | - |
BEXSERO | Phase 2 | Genital Herpes | - | - |
mRNA-1011.2 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1018 for H5 Only-CG | Phase 2 | Influenza | - | - |
mRNA-1018 for H7N9 | Phase 2 | Influenza | - | - |
mRNA-1083.3 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1083 Composition 1 Dose C | Phase 2 | Influenza | - | - |
mRNA-1083 Composition 3 Dose A | Phase 2 | Influenza | - | - |
mRNA-1010.6 | Phase 2 | Influenza | - | - |
mRNA-1018 for H7 Only | Phase 2 | Influenza | - | - |
mRNA-1083 Composition 2 Dose B | Phase 2 | Influenza | - | - |
mRNA-1012.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1020 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1647 | Phase 2 | Cytomegalovirus Infection | - | - |
mRNA-1030 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1769 | Phase 2 | Smallpox | - | - |
mRNA-1608 | Phase 2 | Genital Herpes | - | - |
mRNA-1018 for H5N8 | Phase 2 | Influenza | - | - |
mRNA-3927 | Phase 2 | Propionic Acidemia | - | - |
mRNA-1073 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1283.211 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1468 | Phase 2 | Herpes Zoster | - | - |
mRNA-1893 | Phase 2 | Zika Virus | - | - |
mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Influenza | - | - |
mRNA-3705 | Phase 2 | Methylmalonic Acidemia | - | - |
mRNA-3745 | Phase 2 | Glycogen Storage Disease | - | - |
mRNA-1010.4 | Phase 2 | Influenza | - | - |
Egg-based Quadrivalent Influenza Vaccine | Phase 2 | Influenza | - | - |
mRNA-1195 | Phase 2 | Multiple Sclerosis | - | - |
mRNA-1011.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1405 | Phase 2 | Norovirus Acute Gastroenteritis | - | - |
mRNA-1189 | Phase 2 | Epstein-Barr Virus Infection | - | - |
mRNA-1975 | Phase 2 | Lyme Disease | - | - |
Influenza Vaccine 1 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-2808 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
mRNA-1982 | Phase 2 | Lyme Disease | - | - |
mRNA-1273.214 Vaccine | Phase 2 | COVID-19 Pandemic | - | - |
mRNA-1273.351 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-4359 | Phase 2 | Advanced Solid Tumors | - | - |
IVA | Phase 2 | Cystic Fibrosis | - | - |
mRNA-1083.1 | Phase 2 | SARS-CoV-2 | - | - |
cancer
8 drugs in this indication
Influenza
7 drugs in this indication
COVID-19
6 drugs in this indication
Melanoma
5 drugs in this indication
Respiratory Syncytial Virus
1 drug in this indication
norovirus
1 drug in this indication
Active immunization for the prevention of lower respiratory tract disease caused by RSV
1 drug in this indication
diabetes
1 drug in this indication
Respiratory Syncytial Virus (RSV)
1 drug in this indication
flu
1 drug in this indication
flu prevention
1 drug in this indication
influenza prevention
1 drug in this indication
Ebola
1 drug in this indication
Seasonal Influenza
1 drug in this indication
Resected stage IIB to IV melanoma
1 drug in this indication
Resected stage IIB-IV melanoma (adjuvant)
1 drug in this indication
RNA modification quantification kit (research tool)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Moderna, Inc.'s drug pipeline?→
CatalystAlert tracks 78 drug candidates in Moderna, Inc.'s (MRNA) pipeline across Phase 3, Phase 2. Its lead program is mRNA-1018-H5 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moderna, Inc.'s next FDA catalyst?→
Moderna, Inc.'s (MRNA) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRNA biotech catalysts?→
Add MRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moderna, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
